EP
GALT icon

Essential Partners’s Galectin Therapeutics GALT Stock Holding History

Essential Partners’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$2 – 2711
2025
Q2 		$2 Buy
+1
New +$1 ﹤0.01% 2271

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Essential Partners's GALT Position: Q3 2025 in Review

Essential Partners sold out of Galectin Therapeutics (GALT) in Q3 2025, closing a stake of 1 share — an estimated $2 sold.

Essential Partners first reported a position in GALT in Q2 2025 and held it in 1 quarter. The position peaked at $2 in Q2 2025. 84 funds tracked by Wall St. Rank hold GALT as of Q3 2025.

  • Essential Partners reported no remaining Galectin Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 1 Galectin Therapeutics share in Q3 2025, an estimated $2.
  • Essential Partners first reported a position in Galectin Therapeutics in Q2 2025 and held it in 1 quarter.
  • Essential Partners's Galectin Therapeutics position peaked at $2 in Q2 2025.
  • 84 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.